Passage Bio (PASG) Climbs 7.27% on June 22

Equities Staff  |

Shares of Passage Bio Inc (NASDAQ: PASG) rose 7.27% Wednesday.

As of 12:06:44 est, Passage Bio sits at $2.39 and has moved $0.165 per share in trading so far.

Passage Bio has moved 12.38% over the last 30 days and has a YTD change of 64.25% based on the previous close.

The company anticipates its next earnings on 2022-08-04.

For technical charts, analysis, and more on Passage Bio visit the company profile.

About Passage Bio Inc

Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities it serves. Based in Philadelphia, PA, the company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania's Gene Therapy Program to conduct its discovery and IND-enabling preclinical work. This provides the team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that Passage Bio then pairs with its deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance its robust pipeline of optimized gene therapies into clinical testing. As the company works with speed and tenacity, Passage Bio is always mindful of patients who may be able to benefit from its therapies.

To get more information on Passage Bio Inc and to follow the company's latest updates, you can visit the company's profile page here: Passage Bio Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content